High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*
Open Access
- 29 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1186-1199
Abstract
Background Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis is associated with a high mortality rate. Objectives To investigate drivers of EPC progression. Methods Here, we report the genomic and transcriptomic profiling of mEPC, validation of the observed alterations in an EPC patient-derived cell line, confirmation of relevant observations in a large patient cohort of 30 tumour tissues and successful treatment of a mEPC patient with the identified treatment regimes. Results mEPC was characterized by a high tumour mutational burden with a UV-signature, widespread copy number alterations and gene expression changes that affected cancer-relevant cellular processes like cell cycle regulation and proliferation, including a pathogenic TP53 mutation, a copy number deletion in the CDKN2A region and a CTNND1-PAK1 fusion. The overexpression of EGFR, PAK1, and MAP2K1 (MEK1) genes translated into strong protein expression and respective pathway activation in the tumour tissue. Furthermore, a patient-derived cell line was sensitive to EGFR and MEK inhibition, confirming the functional relevance of the pathway activation. Immunohistochemistry analyses in a large patient cohort showed the relevance of the observed changes to the pathogenesis of EPC. Our results indicate that mEPC should respond to immune or kinase inhibitor therapy. Indeed, the advanced disease of our index patient was controlled by EGFR-directed therapy and immune checkpoint inhibition for more than 2 years. Conclusions Molecular profiling demonstrated high tumour mutational burden and EGFR/MAPK pathway activation as novel therapeutic targets in mEPC.Keywords
This publication has 56 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Recurrent nodules in a periauricular plaque‐type blue nevus with fatal outcomeJournal of Cutaneous Pathology, 2012
- Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical AnalysesPLOS ONE, 2012
- A potential role for targeted therapy in a subset of metastasizing adnexal carcinomasLaboratory Investigation, 2011
- The WTX/AMER1 gene family: evolution, signature and functionBMC Ecology and Evolution, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapyJournal of Hematology & Oncology, 2010
- Pak protein kinases and their role in cancerCancer and Metastasis Reviews, 2009
- Eccrine porocarcinomaDermatologic Therapy, 2008
- Eccrine porocarcinoma of the faceJournal of the American Academy of Dermatology, 1992